Roberto Ciccocioppo Selected Research

CRF receptor type 1

1/2018	Evaluation of Alcohol Preference and Drinking in msP Rats Bearing a Crhr1 Promoter Polymorphism.
10/2017	Hypothalamic CRF1 receptor mechanisms are not sufficient to account for binge-like palatable food consumption in female rats.
8/2014	Role of bed nucleus of the stria terminalis corticotrophin-releasing factor receptors in frustration stress-induced binge-like palatable food consumption in female rats with a history of food restriction.
3/2007	3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto Ciccocioppo Research Topics

Disease

36	Alcoholism (Alcohol Abuse) 01/2022 - 01/2002
17	Substance-Related Disorders (Drug Abuse) 01/2022 - 07/2008
7	Shock 10/2016 - 01/2006
6	Cocaine-Related Disorders (Cocaine Addiction) 01/2018 - 05/2004
6	Bulimia (Binge Eating) 10/2017 - 05/2009
4	Pain (Aches) 01/2022 - 03/2018
4	Opioid-Related Disorders (Opiate Addiction) 01/2021 - 08/2013
4	Substance Withdrawal Syndrome (Withdrawal Symptoms) 12/2019 - 10/2014
3	Obesity 07/2021 - 03/2014
3	Hypersensitivity (Allergy) 02/2021 - 10/2017
3	Type 2 Diabetes Mellitus (MODY) 10/2020 - 04/2011
3	Neuralgia (Stump Neuralgia) 01/2019 - 03/2012
3	Feeding and Eating Disorders (Eating Disorder) 10/2017 - 12/2010
3	Insulin Resistance 12/2016 - 04/2011
3	Tobacco Use Disorder (Nicotine Dependence) 11/2016 - 01/2011
3	Anorexia 12/2006 - 05/2002
2	Body Weight (Weight, Body) 07/2021 - 03/2014
2	Multiple Sclerosis 01/2021 - 01/2010
2	Binge Drinking 10/2020 - 10/2019
2	Cognitive Dysfunction 01/2017 - 09/2007
2	Hyperphagia (Overeating) 01/2016 - 04/2006
2	Mental Disorders (Mental Disorder) 03/2014 - 01/2014
2	Anxiety Disorders (Anxiety Disorder) 07/2013 - 03/2012
2	Partial Epilepsies (Epilepsy, Partial) 07/2013 - 03/2012
1	Neoplasms (Cancer) 01/2022
1	Fatty Liver 07/2021
1	Inflammation (Inflammations) 07/2021
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2019
1	Catalepsy 01/2019
1	Bradycardia 01/2019
1	Hyperalgesia 01/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Heroin Dependence (Heroin Abuse) 01/2018

Drug/Important Bio-Agent (IBA)

15	NociceptinIBA 01/2022 - 05/2002
14	Pharmaceutical PreparationsIBA 01/2022 - 05/2004
13	Ethanol (Ethyl Alcohol)IBA 02/2021 - 01/2002
9	Opioid Analgesics (Opioids)IBA 01/2022 - 12/2014
6	Pioglitazone (Actos)FDA Link 10/2020 - 04/2011
6	Nociceptin ReceptorIBA 01/2019 - 05/2002
5	Biological ProductsIBA 11/2021 - 04/2013
5	NeuropeptidesIBA 01/2019 - 11/2009
5	CannabinoidsIBA 11/2018 - 07/2007
5	Corticotropin-Releasing HormoneIBA 01/2018 - 02/2010
4	CRF receptor type 1IBA 01/2018 - 03/2007
4	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA 10/2017 - 10/2003
3	Peptides (Polypeptides)IBA 01/2022 - 02/2010
3	Neurotransmitter Agents (Neurotransmitter)IBA 03/2021 - 05/2011
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 06/2013
3	Pregabalin (Lyrica)FDA Link 01/2019 - 03/2012
3	Morphine (MS Contin)FDA LinkGeneric 03/2018 - 08/2013
3	Anti-Anxiety Agents (Anxiolytics)IBA 01/2016 - 01/2010
3	gamma-Aminobutyric Acid (GABA)IBA 07/2013 - 03/2012
3	EndocannabinoidsIBA 07/2008 - 07/2007
2	oleoylethanolamideIBA 07/2021 - 01/2016
2	palmidrolIBA 01/2021 - 01/2019
2	Nicotine FDA Link 12/2019 - 01/2011
2	Opioid Peptides (Opioid Peptide)IBA 10/2019 - 01/2003
2	LigandsIBA 10/2019 - 11/2018
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 11/2018 - 07/2008
2	Buprenorphine (Subutex)FDA LinkGeneric 01/2018 - 01/2007
2	anandamide (arachidonylethanolamide)IBA 10/2017 - 07/2008
2	R 121919IBA 10/2017 - 08/2014
2	PesticidesIBA 01/2017 - 01/2013
2	Adrenocorticotropic Hormone (ACTH)FDA Link 11/2016 - 11/2009
2	Antidepressive Agents (Antidepressants)IBA 01/2016 - 03/2014
2	2- (3- (1- (acenaphthen- 1- yl)piperidin- 4- yl)- 2- oxo- 2,3- dihydro- 1H- benzimidazol- 1- yl)- N- methylacetamideIBA 10/2014 - 01/2014
2	Aminobutyrates (Aminobutyric Acid)IBA 07/2013 - 03/2012
2	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 01/2011 - 07/2008
2	Dronabinol (THC)FDA LinkGeneric 01/2010 - 09/2007
1	2- (N- cyclopropylmethyl- 4,5- epoxy- 6,14- ethano- 3- hydroxy- 6- methoxymorphinan- 7- yl)- 3,3- dimethylpentan- 2- olIBA 01/2022
1	polyoxyethyleneamineIBA 07/2021
1	OleylethanolamideIBA 07/2021
1	palmitoleic acidIBA 07/2021
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 04/2021
1	amidaseIBA 01/2021
1	HydrolasesIBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	Cysteine (L-Cysteine)FDA Link 01/2021
1	N-acylethanolaminesIBA 01/2021
1	CarrageenanIBA 01/2021
1	LipidsIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	AcidsIBA 01/2021
1	cis- 1- methyl- 7- ((4- (2,6- dichlorophenyl)piperidin- 1- yl)methyl)- 6,7,8,9- tetrahydro- 5H- benzocyclohepten- 5- olIBA 10/2019
1	salvinIBA 01/2019
1	caryophylleneIBA 01/2019
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2019
1	myrrh resin (myrrh)IBA 01/2019
1	Oleic Acid (Oleate)IBA 11/2018
1	Opioid Receptors (Opioid Receptor)IBA 03/2018
1	CorticosteroneIBA 10/2017
1	Metyrapone FDA Link 10/2017

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2018 - 10/2003
4	Therapeutics 01/2022 - 11/2018
4	Injections 10/2017 - 05/2002
1	Pain Management 01/2022
1	Oral Administration 01/2021
1	Ligation 01/2021
1	Analgesia 01/2019
1	Induced Hypothermia 01/2019